Aier Ophthalmology stated in the investor relations activity record sheet that in the third quarter of 2026, the share of advanced techniques such as ICL V5, full femtosecond Pro, and full photoplastic continued to increase in the company's refractive business. Revenue increased significantly from month to month, and the business structure was clearly optimized.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.